in vitro PHARMACOLOGY 2011 CATALOG - Cerep
in vitro PHARMACOLOGY 2011 CATALOG - Cerep
in vitro PHARMACOLOGY 2011 CATALOG - Cerep
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
168 <strong>in</strong> <strong>vitro</strong> pharmacology <strong>2011</strong> catalog<br />
❚ proteases [ser<strong>in</strong>e proteases]<br />
elastase<br />
❚ Ser<strong>in</strong>e protease<br />
Ref. 0183<br />
Q 3 weeks<br />
Included <strong>in</strong>:<br />
Non-k<strong>in</strong>ase enzyme profile<br />
Organ safety profile<br />
Source<br />
Substrate<br />
Measured product<br />
Detection method<br />
Reference<br />
human leukocytes<br />
MeOSAAPV-pNa (0.1 mM)<br />
pNa<br />
photometry<br />
3’,4’dichloroisocoumar<strong>in</strong> (IC 50 : 392 nM)<br />
Adeyemi, E.O. et al. (1990) J. Pharm. Pharmacol., 42: 487-490.<br />
enzyme activity (% of control)<br />
100<br />
50<br />
0<br />
-8 -7 -6 -5 -4 -3<br />
log [drug] (M)<br />
3',4'dichloroisocoumar<strong>in</strong><br />
PMSF<br />
NDGA<br />
HNE (human neutrophil elastase)<br />
Source<br />
human serum<br />
Substrate<br />
elast<strong>in</strong> fluoresce<strong>in</strong> (1 mg)<br />
Measured product fluoresce<strong>in</strong><br />
❚ Ser<strong>in</strong>e protease<br />
Detection method fluorimetry<br />
Ref. 0562<br />
Reference<br />
3’,4’dichloroisocoumar<strong>in</strong> (IC 50 : 520 nM)<br />
Q 4 weeks<br />
McGillivray, D. H. et al. (1981) Cl<strong>in</strong>. Chim. Acta., 111: 289-294.<br />
enzyme activity (% of control)<br />
100<br />
50<br />
3',4'dichloroisocoumar<strong>in</strong><br />
0<br />
PMSF<br />
-11 -10 -9 -8 -7 -6 -5 -4 -3 -2<br />
log [drug] (M)<br />
kallikre<strong>in</strong><br />
❚ Ser<strong>in</strong>e protease<br />
Ref. 0791<br />
Q 4 weeks<br />
Included <strong>in</strong>:<br />
Organ safety profile<br />
Source<br />
human plasma<br />
Substrate<br />
HDPFR-pNa (50 µM)<br />
Measured product pNa<br />
Detection method photometry<br />
Reference<br />
soybean tryps<strong>in</strong> <strong>in</strong>hibitor (IC 50 : 6 nM)<br />
Nagase, H and Barrett, A.J. (1981) Biochem. J., 193: 187-192.<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
tryptase<br />
❚ Ser<strong>in</strong>e protease<br />
Ref. 0512<br />
Q 3 weeks<br />
Included <strong>in</strong>:<br />
Non-k<strong>in</strong>ase enzyme profile<br />
Organ safety profile<br />
Source<br />
human lung<br />
Substrate<br />
N-p-Tosyl-GPR-pNa (0.1 mM)<br />
Measured product pNa<br />
Detection method photometry<br />
Reference<br />
leupept<strong>in</strong> (IC 50 : 1 µM)<br />
Schwartz, L.B. and Bradford, T.R. (1986) J. Biol. Chem., 261: 7372-7379.<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
caspase-1<br />
100<br />
❚ Cyste<strong>in</strong>e protease<br />
Ref. 3251<br />
Q 3 weeks<br />
Source<br />
human recomb<strong>in</strong>ant (E. coli)<br />
Substrate<br />
benzyloxycarbonyl-YVAD-AFC (7.5 µM)<br />
Measured product AFC<br />
Detection method fluorimetry<br />
Reference<br />
Ac-YVAD-CHO (IC 50 : 20 nM)<br />
Margol<strong>in</strong>, N. et al.(1997) J. Biol. Chem., 272: 7223-7228.<br />
enzyme activity (% of control)<br />
50<br />
0<br />
-10 -9 -8 -7 -6 -5 -4<br />
log [drug] (M)<br />
Ac-YVAD-CHO<br />
Ac-DEVD-CHO<br />
Ac-LEHD-CHO<br />
Ac-IETD-CHO<br />
caspase-2<br />
❚ Cyste<strong>in</strong>e protease<br />
Ref. 0681<br />
Q 6 weeks<br />
Source<br />
human recomb<strong>in</strong>ant (E. coli)<br />
Substrate<br />
benzyloxycarbonyl-VDVAD-AFC (10 µM)<br />
Measured product AFC<br />
Detection method fluorimetry<br />
Reference<br />
Ac-VDVAD-CHO (IC 50 : 130 nM)<br />
Talanian, R.V. et al. (1997) J. Biol. Chem., 272: 9677-9682.<br />
<br />
<br />
<br />
<br />
-10 -9 -8 -7 -6 -5 -4 -3<br />
-11<br />
-10 -9 -8 -7 -6 -5 -4 -3<br />
-12 -11 -10 -9 -8 -7 -6 -5 -4<br />
-11 -10 -9 -8 -7 -6 -5 -4 -3 -2<br />
-10 -9 -8 -7 -6<br />
<br />
<br />
-10 -9 -8 -7 -6 -5 <br />
-4<br />
<br />
-12 -11 -10 -9<br />
<br />
-8 -7 -6 -5 -4 -3<br />
-12 -11 -10 -9 -8 -7 -6 -5<br />
-11<br />
-10 -9 -8 -7 -6 -5 -4